Larimar Therapeutics, Inc.
HealthcareNASDAQ:LRMR · NASDAQ Global Market
-$0.13 today
Vol 1.56M · Avg 2.13M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $177.9M |
| Short-term Investments | $22.5M |
| Other Current | $4.6M |
| Total Current Assets | $205.0M |
| PP&E (Net) | $2.4M |
| Other Non-current | $1.1M |
| Total Non-current Assets | $3.5M |
| Total Assets | $208.5M |
Analysis
Selected assets total $208.5M for Latest. The largest visible component is Cash & Equivalents at $177.9M, about 85.3% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $85.4M +157.1% | $33.2M +24.2% | $26.7M -0.3% | $26.8M -61.7% | $70.1M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $51.4M -65.8% | $150.2M +150.2% | $60.0M -34.5% | $91.6M | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $747.0K -29.1% | $1.1M | $0 | $0 -100.0% | $208.0K | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $4.4M -59.0% | $10.8M +1422.7% | $709.0K +197.9% | $238.0K -14.7% | $279.0K | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $142.0M -27.3% | $195.3M +116.6% | $90.2M -25.3% | $120.7M +67.2% | $72.2M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $2.7M -27.6% | $3.7M -1.1% | $3.8M +2.0% | $3.7M -17.2% | $4.5M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 -100.0% | $1.3M | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $1.1M -6.1% | $1.2M +82.4% | $659.0K -66.7% | $2.0M -1.5% | $2.0M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $3.8M -22.4% | $4.9M -14.6% | $5.8M +1.7% | $5.7M -12.3% | $6.5M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $145.8M -27.2% | $200.2M +108.7% | $95.9M -24.1% | $126.4M +60.7% | $78.7M | $13.3B | $11.9B | $10.6B |
| Account Payables | $5.2M +115.2% | $2.4M +88.9% | $1.3M -23.9% | $1.7M +1.6% | $1.7M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $1.1M | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $58.5M | $0 | $0 | $0 | $0 | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $64.8M +166.0% | $24.4M +156.2% | $9.5M -11.2% | $10.7M +21.0% | $8.8M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $0 | $0 | $0 | $0 | $0 | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $3.0M -27.0% | $4.1M -13.8% | $4.7M -1.8% | $4.8M -11.3% | $5.4M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $67.8M +138.5% | $28.4M +99.9% | $14.2M -8.3% | $15.5M +8.8% | $14.3M | $14.7B | $3.7B | $9.6B |
| Common Stock | $83.0K +29.7% | $64.0K +48.8% | $43.0K +0.0% | $43.0K +138.9% | $18.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$434.8M -61.6% | -$269.2M -42.7% | -$188.6M -24.4% | -$151.6M -30.4% | -$116.3M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $54.0K -63.5% | $148.0K +82.7% | $81.0K +361.3% | -$31.0K | $0 | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $78.1M -54.6% | $171.8M +110.2% | $81.7M -26.3% | $110.9M +72.2% | $64.4M | $9.1B | $7.7B | $3.3B |
| Total Debt | $4.1M -20.5% | $5.1M -7.7% | $5.5M +2.6% | $5.4M -9.9% | $6.0M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$81.3M -189.5% | -$28.1M -32.5% | -$21.2M +1.0% | -$21.4M +66.6% | -$64.1M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Alto Neuroscience, Inc.
NYSE:ANRO
$753.47M
Annexon, Inc.
NASDAQ:ANNX
$563.29M
DBV Technologies S.A.
NASDAQ:DBVT
$416.60M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$352.74M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$343.14M
Amarin Corporation plc
NASDAQ:AMRN
$315.21M
AC Immune S.A.
NASDAQ:ACIU
$235.10M
Altimmune, Inc.
NASDAQ:ALT
$230.35M
Korro Bio, Inc.
NASDAQ:KRRO
$115.56M
enGene Holdings Inc.
NASDAQ:ENGN
$82.94M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does LRMR have?
Larimar Therapeutics, Inc. (LRMR) reported $85.41M in cash and equivalents in fiscal 2025.
How much debt does LRMR carry?
Larimar Therapeutics, Inc. (LRMR) reported $4.07M of total debt, with net debt of -$81,345,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.